Q6 9 10 COVID-19 has rapidly developed 11 into a worldwide pandemic with 12 a significant health and economic 13 burden. There are currently no 14 approved treatments or preventative 15 therapeutic strategies. Hundreds 16 of clinical studies have been 17 registered with the intention of 18 discovering effective treatments. 19 Here, we review currently registered 20 interventional clinical trials for 21 the treatment and prevention of 22 COVID-19 to provide an overall 23 summary and insight into the global 24 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 identified several genomic regions of interest 75 for therapeutic modulation, specifically the 76 identification of highly conserved regions 77 involving viral enzymes between different 78 pathogenic coronaviruses. Journal Editors (ICMJE) that all clinical 84 trials should be registered in publicly 85 available domains before they may be 86 considered for publication [8]. The intro-87 duction of this requirement and other 88 initiatives to increase clinical trial trans-89 parency has contributed to an increasing 90 number of trials being recorded in online 91 registries, such as ClinicalTrials.gov v 92 and the International Clinical Trials 93 Registry Platform (ICTRP) vi of the WHO. 94 The logging of trials on registries has 95 vastly facilitated the dissemination of 96 information across several domains, 97 including intervention, methodology, 98 patient group, and outcome measures.
F spread rapidly and now affects all permanently inhabited continents. This is the greatest pandemic of modern times and has been declared a Public Health Emergency of International Concern by the WHO Director-General ii . As of 27 March 2020 (date of submission), COVID-19 was affecting 199 countries and territories, with N510 000 confirmed cases globally iii . It is associated with an estimated mortality of between 1% and 5% iii . Furthermore, human-tohuman transmission has continued apace, despite escalating public health measures. Current estimates of the impact on the worldwide economy are US$1 trillion and rising iv .
Currently, there are no approved therapies for either the treatment or prevention of COVID-19. With the predicted number of cases set to rise significantly, this represents a prodigious acute unmet medical need. Several national and international research groups are working collaboratively on a variety of preventative and therapeutic interventions. Potential avenues being explored include vaccine development, convalescent plasma, interferon-based therapies, small-molecule drugs, cell-based therapies, and monoclonal antibodies (mAbs) [5] . However, drug therapy development is a costly and timely process with a high attrition rate [6] . The speed of the normal drug development pathway is unacceptable in the context of the current global emergency. Therefore, there has been considerable interest in repurposing existing drugs and expediting developmental antiviral treatments, such as those for influenza, hepatitis B (HBV), hepatitis C (HCV), and filoviruses, to allow more rapid development [5] . The swift genomic sequencing of COVID-19 has facilitated this process, allowing comparison with MERS-CoV, SARS-CoV, and other morbific viruses [7] . This strategy has Glossary Adalimumab: mAb targeted against TNF-α; an immunosuppressant commonly used in inflammatory conditions. Anti-PD-1 antibody: antibody against Programmed Cell Death Protein 1 (PD-1); inhibition of PD-1 can reverse immune exhaustion; used in oncology treatment (e.g., melanoma). ASC09: HIV protease inhibitor; under development by Ascletis Pharmaceuticals. Aviptadil: a vasodilator and short-acting alphaadrenoreceptor antagonist. Azvudine: nucleoside reverse transcriptase inhibitor with efficacy against HCV and HIV. Baloxavir marboxil: polymerase acidic endonuclease inhibitor approved for influenza. Bevacizumab: mAb targeting vascular endothelial growth factor (VEGF). Bismuth: oral medication used in treatment of Helicobacter pylori; some evidence of inhibition of SARS coronavirus helicase ATPase. Blinding: experimental procedure in which the participant, investigator, care provider, or outcome assessor in a clinical trial are unaware of which treatment arm the participant is receiving. Studies can be described as the number of roles that are blinded (i.e., single, double or quadruple-blinded study). Blinding reduces the risk of bias in the outcome of a trial. Carrimycin: macrolide antibiotic. Cytokine-induced killer cells (CIK cell): CD8+ T cells expanded from ex vivo stimulation of lymphocytes; used in experimental immunotherapy. Cobicistat: CYP3A inhibitor licensed for use in HIV; potentiates action of other antiviral medication. CytoSorb: device used in conjunction with dialysis, haemofiltration or extracorporeal membrane oxygenation. Danoprevir: NS3/4A protease inhibitor used in treatment of HCV. Darunavir: HIV protease inhibitor. Dexmedetomidine: sedative α2-adrenergic receptor agonist. Dihydroartemisinin/piperaquine: combination antimalarial medication. Dipyridamole: antiplatelet medication that is a phosphodiesterase inhibitor; exerts antiviral effects via inhibition of nucleoside uptake. Double-blind: where two groups within a study, typically the participant and the outcome assessor, are blinded to the treatment received by the participant. Ebastine: H 1 receptor antagonist. Eculizumab: mAb that inhibits activation of complement protein C5; used in thrombotic microangiopathy. Emtricitabine/tenofovir: combination nucleoside reverse transcriptase inhibitor used in the treatment of HIV-1. Enoxaparin: low-molecular-weight heparin, an anticoagulant. 
not been further analysed due to a lack of scientific rationale, inadequate provision of information regarding active ingredients, and limited applicability to mainstream medical practice. Table 1 (Key  Table) shows interventional treatments (Table 1A ) and preventative strategies (Table 1B) under clinical investigation for COVID-19.
Treatment Strategies

Antiviral Treatments
As briefly mentioned earlier, many studies have focused on repurposing established antiviral therapies, especially those that showed prior efficacy against SARS-CoV and MERS-CoV. The combination of lopinavir/ritonavir is the most common exploratory antiviral, appearing in 34 investigational studies (Table 1A : Antivirals). Both drugs function as protease inhibitors and are used extensively in the management of HIV-1 [9]. However, lopinavir has insufficient oral bioavailability for significant therapeutic activity, due to rapid catabolism by the cytochrome P450 enzyme system (specifically 3A4 isoenzyme) [9] . Thus, ritonavir is given concomitantly to inhibit this, significantly boosting the half-life of lopinavir. Lopinavir/ ritonavir was investigated for efficacy against SARS-CoV in 2004 and found to be effective compared with a historical control [10]. However, efficacy was not seen in a randomised open-label study (see Glossary) (lopinavir/ritonavir versus standard care) in 199 patients with COVID-19 (Clinical Trial Number: ChiCTR2000029308, recruitment target stated as 160 participants in the registry; Table 1 ). No significant benefit was seen in either overall mortality or reduction in viral load [11] . The authors highlighted several limitations, including a lack of treatment blinding, with study participants and investigators being aware of treatment assignments, thus reducing study objectivity. While there are multiple other ongoing studies exploring lopinavir/ ritonavir in COVID-19, none utilises a Favipiravir: RNA-dependent RNA polymerase inhibitor, investigated against RNA viruses, such as Influenza, Ebola and Marburg viruses. GD31: described within the trial report as novel nucleoside analogue. Interferon alpha: cytokine used in the treatment of chronic viral infections, such as HBV and HCV. Interferon beta 1b: cytokine used in the treatment of multiple sclerosis. Leflunomide: immunosuppressive used in the treatment of rheumatoid arthritis. Lipoic acid: antioxidant. Losartan: angiotensin-II receptor antagonist. Novaferon: recombinant interferon-like protein; in vitro and in vivo model evidence of more potent activity compared with interferon. Open-label: a study in which the treatment received by the participant is known to both the participant and investigators. Oseltamivir: neuraminidase inhibitor; licenced for influenza A and B treatment. Pegasys: pegylated interferon alpha 2a. Polyinosinic-polycytidylic acid: immunostimulant; TLR3 agonist. PUL-042: immunostimulant; TLR2/6/9 agonist. Randomised study: a trial in which the treatment or intervention is randomly allocated to a participant. Randomisation reduces the risk of bias in a trial outcome. Recombinant IL-2: cytokine used in cancer immunotherapy treatment (e.g., melanoma). Ribavirin: guanosine analogue; antiviral agent used against a range of morbific viral infections (e.g., HCV, human respiratory syncytial virus, and Lassa virus). Ruxolitinib: selective inhibitor of Janus Kinase type 1 and 2; used within haematology against polycythaemia vera and myelofibrosis. Sildenafil: phosphodiesterase type 5 inhibitor; vasodilator used commonly for erectile dysfunction and pulmonary arterial hypertension. Single-arm trial: only one treatment or intervention is being assessed. Q9 Sodium aescinate: saponin extract of Aesculus hippocastanum seeds; investigated for use in lung injury. Sofosbuvir/daclatasvir: combination mediation used in treatment of HCV. Sofosbuvir is a nucleotide prodrug and acts as an inhibitor of HCV NS5B RNAdependant RNA polymerase. Daclatasvir is an HCV NS5A inhibitor. Sofosbuvir/ledipasvir: combination mediation used in treatment of HCV; Ledipasvir is an inhibitor of HCV NS5A protein.
Stem cell educator therapy: circulation of patient blood through a cell separator followed by brief coculture of immune cells with cord-blood stem cells and return of the educated immune cells to the patient's circulation. Suramin: antitrypanosomal drug used in treatment of African trypanosomiasis. Tetrandrine: bisbenzylisoquinoline alkaloid; a calcium channel blocker with anti-inflammatory and immunosuppressant properties. (Table 1A : Antifibrotics and 290 Antiangiogenics). A further five studies 291 aim to assess the therapeutic utility of 292 modifying the gut microbiome (Table 1A : 293 Microbiome), although the mechanisms 294 by which this is performed are not explicit 295 in the trial registers. Ten other studies 296 are investigating holistic approaches, 297 including physiotherapy, psychology, 298 and nutritional intervention, on disease 299 outcome (Table 1A : Therapy Interventions).
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Preventative Strategies
Over 50 novel vaccines are estimated to be in development; however, only three vaccine studies are registered for Phase I evaluation (Table 1B: Vaccines) . Two studies are actively recruiting in the USA and China, and a further study is newly registered (initial set-up). A modified mRNA vaccine (mRNA-1273) that encodes the COVID-19 viral spike protein has progressed rapidly through preclinical development to human testing (42 days from sequence identification), developed by Moderna, Inc and the National Institute of Allergy and Infectious Diseases (NIAID). However, such rapid development has prompted safety concerns from some experienced virologists [25] . Other current investigational vaccines being tested in humans include a replicative-defective adenovirus type 5 (Ad5)-nCoV that expresses COVID-19 viral proteins and a lentiviral vector system to express viral proteins and immunomodulatory genes to modify antigen-presenting cells (aAPC) ( Table 1B: Vaccines) .
Furthermore, postexposure prophylaxis is an attractive strategy for both healthcare 318 workers and household contacts exposed 
